AMANTADINE (AMANTADINE HCL)
- Idiopathic parkinsonism
- Arteriosclerotic parkinsonism
- Drug-induced extrapyramidal reaction
- Parkinsonism
- Postencephalitic parkinsonism
HCl 50 mg/5 mL oral solution
- 10 milliliters (100 mg) by oral route 2 times per day
HCl 50 mg/5 mL oral solution
- 10 milliliters (100 mg) by oral route 2 times per day
Arteriosclerotic parkinsonism
- 10 milliliters (100 mg) by oral route 2 times per day
- 20 milliliters (200 mg) by oral route 2 times per day
Drug-induced extrapyramidal reaction
- 10 milliliters (100 mg) by oral route once daily
- 10 milliliters (100 mg) by oral route 2 times per day
- 20 milliliters (200 mg) by oral route once daily
Fatigue due to multiple sclerosis
- 10 milliliters (100 mg) by oral route once daily
- 10 milliliters (100 mg) by oral route 2 times per day
- 20 milliliters (200 mg) by oral route once daily
Idiopathic parkinsonism
- 10 milliliters (100 mg) by oral route 2 times per day
- 20 milliliters (200 mg) by oral route 2 times per day
Parkinsonism
- 10 milliliters (100 mg) by oral route once daily
- 10 milliliters (100 mg) by oral route 2 times per day
- 20 milliliters (200 mg) by oral route once daily
Postencephalitic parkinsonism
- 10 milliliters (100 mg) by oral route 2 times per day
- 20 milliliters (200 mg) by oral route 2 times per day
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
Contraindicated
- amiodarone
- amiodarone in dextrose,iso-osm
- artemether-lumefantrine
- Coartem
- Cordarone
- disopyramide
- dronedarone
- droperidol
- Geodon
- memantine
- Multaq
- Namenda
- Namenda Titration Pak
- Namenda Xr
- Nexterone
- Norpace
- Norpace Cr
- Orap
- Pacerone
- pimozide
- thioridazine
- ziprasidone HCl
- ziprasidone mesylate
Severe
Moderate
- Ablavar
- acetazolamide
- acetazolamide sodium
- Al hyd-Mg tr-alg ac-sod bicarb
- alfuzosin
- Alka-seltzer Gold
- Alka-seltzer Heartburn
- Antacid Tablet
- Anzemet
- Apokyn
- apomorphine
- arsenic trioxide
- Avelox
- Avelox Abc Pack
- Avelox In Nacl (iso-osmotic)
- bedaquiline
- Betapace
- Betapace Af
- Caprelsa
- Celexa
- Cipro
- Cipro In D5W
- Cipro Xr
- ciprofloxacin
- ciprofloxacin (mixture)
- ciprofloxacin in D5W
- citalopram
- clozapine
- Clozaril
- Complera
- crizotinib
- Cytra K Crystals
- Cytra-2
- Cytra-3
- Cytra-k
- dasatinib
- Diamox Sequels
- Diskets
- dofetilide
- dolasetron
- Dolophine
- E-z-gas Ii
- Edurant
- emtricitab-rilpivirine-tenofov
- eribulin
- escitalopram oxalate
- ezogabine
- Fareston
- Fazaclo
- Foaming Antacid
- gadofosveset trisodium
- Gaviscon
- Halaven
- Haldol
- Haldol Decanoate
- haloperidol
- haloperidol decanoate
- haloperidol lactate
- Invega
- Invega Sustenna
- Invirase
- Istodax
- K-phos No 2
- K-phos Original
- K-phos-neutral
- Kaletra
- lapatinib
- Levaquin
- Levaquin In 5 % Dextrose
- levofloxacin
- levofloxacin in D5W
- Lexapro
- lopinavir-ritonavir
- methadone
- Methadone Intensol
- Methadose
- methazolamide
- methenamine mand-sod biphos
- moxifloxacin
- moxifloxacin in NaCl (iso-osm)
- Neptazane
- Neut
- Nexavar
- nilotinib
- norfloxacin
- Noroxin
- Noxafil
- ondansetron
- ondansetron HCl
- ondansetron HCl (PF)
- Oracit
- paliperidone
- paliperidone palmitate
- pasireotide
- pazopanib
- Phospha 250 Neutral
- posaconazole
- pot & sod citrate-citric acid
- potassium citrate
- potassium citrate-citric acid
- potassium phosphate, monobasic
- potassium&sodium monobas phos
- Potiga
- propafenone
- Qualaquin
- quetiapine
- quinine sulfate
- rilpivirine
- romidepsin
- Rythmol
- saquinavir mesylate
- Seroquel
- Seroquel Xr
- Signifor
- Sirturo
- sod bicarb-citric ac-simeth
- sod phos,di & mono-K phos mono
- sodium & potassium bicarbonate
- sodium acetate
- sodium bicarb & citrate
- sodium bicarbonate
- sodium citrate-citric acid
- sodium lactate
- sorafenib
- Sorine
- sotalol
- Sotalol Af
- Sprycel
- Taron-crystals
- Tasigna
- telavancin
- tetrabenazine
- Tham
- Tikosyn
- toremifene
- Tricitrates
- Trisenox
- tromethamine
- Tykerb
- Urocit-k 10
- Urocit-k 15
- Urocit-k 5
- Uroqid-acid No.2
- Uroxatral
- vandetanib
- vemurafenib
- Versacloz
- Vibativ
- Votrient
- Xalkori
- Xenazine
- Zelboraf
- Zofran
- Zofran Odt
- Zuplenz
- None
Contraindicated
- Angle-closure glaucoma
- Drug abuse
- Kidney disease with reduction in GFR
- Psychotic disorder
- Seizure disorder
- Suicidal ideation
Severe
Moderate
- Chronic heart failure
- Eczema
- Edema
- Malignant melanoma
- Orthostatic hypotension
AMANTADINE (AMANTADINE HCL)
- Idiopathic parkinsonism
- Arteriosclerotic parkinsonism
- Drug-induced extrapyramidal reaction
- Parkinsonism
- Postencephalitic parkinsonism
- Accidental fall
- Anorexia
- Concentration difficulty
- Constipation
- Dizziness
- Hallucinations
- Headache disorder
- Insomnia
- Nausea
- Nervousness
- Orthostatic hypotension
- Peripheral edema
- Xerostomia
More Frequent
Severe
Less Severe
- None
- Acute confusion
- Blurred vision
- Cough
- Depression
- Diarrhea
- Dream disorder
- Drowsy
- Fatigue
- Irritability
- Livedo reticularis
- Nightmares
- Symptoms of anxiety
- Urinary tract infection
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Agranulocytosis
- Chronic heart failure
- Corneal deposits
- Neutropenic disorder
- Paranoid disorder
- Seizure disorder
- Suicidal
- Suicidal ideation
Less Severe
- Allergic dermatitis
- Delusional disorder
- Dry nose
- Dry throat
- Impulse control disorder
- Skin rash
- Urinary retention
- Visual changes
- Vomiting
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Amantadine
Safety and efficacy not established age <1 year.
- 1 Day – 364 Days
- Safety and efficacy not established age <1 year.
Amantadine
- Severity Level:
C
- Additional Notes:
Contraindicated
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Precaution Exists
Amantadine
Not recommended by mfr; may decrease prolactin levels.
General | Excretion Potential | Effect on Infant | Notes |
Evaluate use carefully | Excreted | Not known; no or inclusive data | Not recommended by mfr; may decrease prolactin levels. |
No Known Risk
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Contraindicated
None
Precaution Exists
Amantadine
Neuro/Psych-Anticholinergic effects cause sedation, worsen cognitive impairment and increase fall risk. Renal-Decrease dose for CrCL<50 mL/min. Cardiovascular-May cause orthostatic hypotension. Use cautious dosing in heart failure patients. Gastrointestinal-May cause or worsen pre-existing constipation. Genitourinary-Best avoided in patients with urinary retention from any cause.
Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
Increased Risk / Adverse Effects | Y | Y | Y | Y | N | N |
BEERS: N HEDIS: N STOPP: Y
No Known Risk
None
- None
Arteriosclerotic parkinsonism | |
G21.4 | Vascular parkinsonism |
Drug-induced extrapyramidal reaction | |
G25 | Other extrapyramidal and movement disorders |
G25.7 | Other and unspecified drug induced movement disorders |
G25.70 | Drug induced movement disorder, unspecified |
G25.79 | Other drug induced movement disorders |
G25.8 | Other specified extrapyramidal and movement disorders |
G25.89 | Other specified extrapyramidal and movement disorders |
G25.9 | Extrapyramidal and movement disorder, unspecified |
Idiopathic parkinsonism | |
G20 | Parkinson's disease |
Parkinsonism | |
G20 | Parkinson's disease |
G21 | Secondary parkinsonism |
G21.2 | Secondary parkinsonism due to other external agents |
G21.3 | Postencephalitic parkinsonism |
G21.4 | Vascular parkinsonism |
G21.8 | Other secondary parkinsonism |
G21.9 | Secondary parkinsonism, unspecified |
Postencephalitic parkinsonism | |
G21.3 | Postencephalitic parkinsonism |
0-9 | A-Z |
---|---|
G20 | Parkinson's disease |
G20 | Parkinson's disease |
G21 | Secondary parkinsonism |
G21.2 | Secondary parkinsonism due to other external agents |
G21.3 | Postencephalitic parkinsonism |
G21.3 | Postencephalitic parkinsonism |
G21.4 | Vascular parkinsonism |
G21.4 | Vascular parkinsonism |
G21.8 | Other secondary parkinsonism |
G21.9 | Secondary parkinsonism, unspecified |
G25 | Other extrapyramidal and movement disorders |
G25.7 | Other and unspecified drug induced movement disorders |
G25.70 | Drug induced movement disorder, unspecified |
G25.79 | Other drug induced movement disorders |
G25.8 | Other specified extrapyramidal and movement disorders |
G25.89 | Other specified extrapyramidal and movement disorders |
G25.9 | Extrapyramidal and movement disorder, unspecified |